The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
Abstract
Cytotoxic T lymphocyte (CTL) peptide epitopes can be used for immunization of mice against lethal virus infection. To study whether this approach can be successful against virus‐induced tumors we generated a B6 (H‐2 b) tumorigenic cell line transformed by human papillomavirus (HPV). This virus is detected in over 90% of all human cervical cancers. To identify vaccine candidates, we generated a set of 240 overlapping peptides derived from the HPV type 16 (HPV16) oncogenes E6 and E7. These peptides were tested for their ability to bind H‐2K b and H‐2D b MHC class I molecules. Binding peptides were compared with the presently known peptide‐binding motifs for H‐2K b and H‐2D b and the predictive value of these motifs is shortly discussed. The high‐affinity H‐2D b‐binding peptide and putative CTL epitope E 7 49‐57 (RAHYNIVTF) was used in vaccination studies against HPV 16‐transformed tumor cells. Immunization with peptide E 7 49‐57 rendered mice insensitive to a subsequent challenge with HPV 16‐transformed tumor cells in vivo, and induced a CTL response which lysed the tumor cells in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
Falk, K., Rötzschke, O., Stevanovié, S., Jung, G., & Rammensee, H.-G. (1991) · Nature · doi:10.1038/351290a0 · Cited by 2,411
Delves, P. J., & Roitt, I. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007063430107 · Cited by 1,666
Estimates of the worldwide frequency of sixteen major cancers in 1980
Parkin, D. M., Läärä, E., & Muir, C. S. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410205 · Cited by 1,047
Empty MHC class I molecules come out in the cold
Ljunggren, H.-G., Stam, N. J., Öhlén, C., Neefjes, J. J., Höglund, P., Heemels, M.-T., Bastin, J., Schumacher, T. N. M., Townsend, A., Kärre, K., et al. (1990) · Nature · doi:10.1038/346476a0 · Cited by 926
Baker, C. C., Phelps, W. C., Lindgren, V, Braun, M. J., Gonda, M. A., & Howley, P. M. (1987) · Journal of Virology · doi:10.1128/jvi.61.4.962-971.1987 · Cited by 757
Ozato, K., & Sachs, D. H. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.126.1.317 · Cited by 571
Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA
Pirisi, L., Yasumoto, S., Feller, M., Doniger, J., & DiPaolo, J. A. (1987) · Journal of Virology · doi:10.1128/jvi.61.4.1061-1066.1987 · Cited by 528
Resnick, R. M., Cornelissen, M. T. E., Wright, D. K., Eichinger, G. H., Fox, H. S., Schegget, J. T., & Manos, M. M. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.18.1477 · Cited by 452
Self-citation
Cited by
MHC ligands and peptide motifs: first listing
Rammensee, H.-G., Friede, T., & Stevanović, S. (1995) · Immunogenetics · doi:10.1007/bf00172063 · Cited by 1,638
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Self-citationMelief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Self-citationA p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Self-citationStructure-based programming of lymph-node targeting in molecular vaccines
Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Van Egeren, D. S., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 943
Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethé, B., Brasseur, F., & Boon, T. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.921 · Cited by 762
Dendritic Cells in Cancer Immunotherapy
Fong, L., & Engleman, E. G. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.245 · Cited by 680
The role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672
Ossendorp, F., Mengedé, E., Camps, M., Filius, R., & Melief, C. J. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.5.693 · Cited by 610
Self-citationImmunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2373 · Cited by 594
Self-citationMechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells
Gabrilovich, D. I., Velders, M. P., Sotomayor, E. M., & Kast, W. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5398 · Cited by 538
Self-citationDiehl, L., den Boer, A. T., Schoenberger, S. P., van der Voort, E. I. H., Schumacher, T. N. M., Melief, C. J. M., Offringa, R., & Toes, R. E. M. (1999) · Nature Medicine · doi:10.1038/10495 · Cited by 469
Self-citationPardoll, D. M. (1998) · Nature Medicine · doi:10.1038/nm0598supp-525 · Cited by 428
Zwaveling, S., Mota, S. C. F., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H., & Melief, C. J. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.350 · Cited by 417
Self-citationCancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., & Anichini, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.805 · Cited by 401
Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S. M., & Gabrilovich, D. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0529 · Cited by 318
Celis, E., Tsai, V, Crimi, C., DeMars, R., Wentworth, P. A., Chesnut, R. W., Grey, H. M., Sette, A., & Serra, H. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2105 · Cited by 306
Tumor-infiltrating T lymphocytes: Friends or foes?
Yu, P., & Fu, Y.-X. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700389 · Cited by 299
Gunn, G. R., Zubair, A., Peters, C., Pan, Z.-K., Wu, T.-C., & Paterson, Y. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6471 · Cited by 298
Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.
Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J., & Kast, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7855 · Cited by 292
Self-citationCheng, W.-F., Hung, C.-F., Chai, C.-Y., Hsu, K.-F., He, L., Ling, M., & Wu, T.-C. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12346 · Cited by 281
Bijker, M. S., van den Eeden, S. J. F., Franken, K. L., Melief, C. J. M., Offringa, R., & van der Burg, S. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5033 · Cited by 279
Self-citationCell-Mediated Immune Response to Human Papillomavirus Infection
Scott, M., Nakagawa, M., & Moscicki, A.-B. (2001) · Clinical Diagnostic Laboratory Immunology · doi:10.1128/cdli.8.2.209-220.2001 · Cited by 273
Human papillomavirus infection: biology, epidemiology, and prevention
SCHEURER, M. E., TORTOLERO-LUNA, G., & ADLER-STORTHZ, K. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00246.x · Cited by 260
Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R., & Chen, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14184 · Cited by 259
MHC Class I–Restricted CTL Responses to Exogenous Antigens
Jondal, M., Schirmbeck, R., & Reimann, J. (1996) · Immunity · doi:10.1016/s1074-7613(00)80255-1 · Cited by 253
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Marijt, K. A., Sluijter, M., Blijleven, L., Tolmeijer, S. H., Scheeren, F. A., van der Burg, S. H., & van Hall, T. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0627-8 · Cited by 85
Critical role for the Ly49 family of class I MHC receptors in adaptive natural killer cell responses
Wight, A., Mahmoud, A. B., Scur, M., Tu, M. M., Rahim, M. M. A., Sad, S., & Makrigiannis, A. P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1722374115 · Cited by 35
“Along similar lines, we tested the ability of an H-2D restricted peptide, RAHYNIVTF (19), to provoke NK memory responses and confirmed that H-2D is just as capable as H-2K at presenting peptide to NK cells (Fig.”
MethodDesign and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines
Song, K., & Pun, S. H. (2024) · BME Frontiers · doi:10.34133/bmef.0038 · Cited by 20
Metadata
- Authors
- Feltkamp, M. C. W., Smits, H. L., Vierboom, M. P. M., Minnaar, R. P., De Jongh, B. M., Drijfhout, J. W., Schegget, J. T., Melief, C. J. M., & Kast, W. M.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 1993-09
- Volume
- 23
- Issue
- 9
- Pages
- 2242-2249
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1978146796
- Cited by
- 825
- References
- 32
- FWCI
- 14.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.